% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kratochwil:126920,
      author       = {C. Kratochwil$^*$ and M. Stefanova$^*$ and E.
                      Mavriopoulou$^*$ and T. Holland-Letz$^*$ and A.
                      Dimitrakopoulou-Strauss$^*$ and A. Afshar-Oromieh$^*$ and W.
                      Mier$^*$ and U. Haberkorn$^*$ and F. Giesel$^*$},
      title        = {{SUV} of [68{G}a]{DOTATOC}-{PET}/{CT} {P}redicts {R}esponse
                      {P}robability of {PRRT} in {N}euroendocrine {T}umors.},
      journal      = {Molecular imaging $\&$ biology},
      volume       = {17},
      number       = {3},
      issn         = {1860-2002},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2017-02948},
      pages        = {313 - 318},
      year         = {2015},
      abstract     = {The goal of our study was to quantify the expression of the
                      somatostatin receptors (SSTR2) using the maximum
                      standardized uptake value (SUVmax) of
                      [(68)Ga]DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) positron
                      emission tomography (PET)-computed tomography (CT) in liver
                      metastases of patients with neuroendocrine tumors (NETs)
                      prior to peptide receptor radiation therapy (PRRT) and
                      compare the initial tumor uptake with the final treatment
                      outcome.SSTR2 expression of the 60 liver metastases in 30
                      NET patients was assessed at baseline and after PRRT by
                      measuring SUVmax, tumor to spleen ratio (T/S ratio), and
                      tumor to liver ratio (T/L ratio). Based on morphological
                      changes and tumor size measured at baseline and follow-up
                      contrast-enhanced CT (after three cycles of PRRT), lesions
                      were divided into two groups by the following: (i)
                      responding (n = 40) and (ii) non-responding
                      (n = 20).Statistically significant differences were
                      observed in the mean SUVmax for non-responding vs.
                      responding lesions at baseline (18.00 ± 3.59 vs.
                      33.55 ± 4.62, p < 0.05) and for the mean T/S ratio
                      (1.20 ± 0.37 vs. 1.90 ± 0.45, p < 0.05) and
                      the mean T/L ratio (3.15 ± 0.53 vs. 4.97 ± 0.62,
                      p < 0.05). Using the receiver operating characteristic
                      curves, SUVmax was found a better metric than both T/L ratio
                      and T/S ratio (area under the curve (AUC) of SUVmax 0.87;
                      T/L ratio 0.78; T/S ratio 0.73) as a stratification
                      criterion. Using a threshold value of >16.4 for SUVmax, the
                      sensitivity and specificity in predicting responding lesions
                      were 95 and 60 $\%,$ respectively.We propose a SUVmax cutoff
                      of >16.4 from [(68)Ga]DOTATOC-PET-CT to select patients for
                      PRRT. A T/L ratio >2.2 might present a scanner-independent
                      criterion that enables the translation of our results to
                      other institutions. However, the robustness of this
                      arbitrary unit still needs to be evaluated with different
                      PET scanners.},
      keywords     = {Contrast Media (NLM Chemicals) / Ga(III)-DOTATOC (NLM
                      Chemicals) / Organometallic Compounds (NLM Chemicals) /
                      Peptides (NLM Chemicals) / Radiopharmaceuticals (NLM
                      Chemicals) / Receptors, Somatostatin (NLM Chemicals) /
                      somatostatin receptor subtype 2, human (NLM Chemicals) /
                      Octreotide (NLM Chemicals)},
      cin          = {E060 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)E060-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25319765},
      doi          = {10.1007/s11307-014-0795-3},
      url          = {https://inrepo02.dkfz.de/record/126920},
}